[1]朱海燕,陈淑琴,周 琴.温肺祛痰散对稳定期慢性阻塞性肺疾病患者外周血T淋巴细胞、血清IL-2及sIL-2R的影响[J].陕西中医,2025,46(1):60-63.[doi:DOI:10.3969/j.issn.1000-7369.2025.01.012]
　ZHU Haiyan,CHEN Shuqin,ZHOU Qin.Effect of Wenfei Qutan powder on peripheral blood T Lymphocytes,serum IL-2 and sIL-2R in stable chronic obstructive pulmonary disease patients[J].,2025,46(1):60-63.[doi:DOI:10.3969/j.issn.1000-7369.2025.01.012]
点击复制

温肺祛痰散对稳定期慢性阻塞性肺疾病患者外周血T淋巴细胞、血清IL-2及sIL-2R的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年1期
页码:
60-63
栏目:
临床研究
出版日期:
2025-01-05

文章信息/Info

Title:
Effect of Wenfei Qutan powder on peripheral blood T Lymphocytes,serum IL-2 and sIL-2R in stable chronic obstructive pulmonary disease patients
作者:
朱海燕; 陈淑琴; 周 琴
(张家港市中医医院,江苏 张家港 215600)
Author(s):
ZHU Haiyan; CHEN Shuqin; ZHOU Qin
(Zhangjiagang Hospital of Traditional Chinese Medicine,Zhangjiagang 215600,China)
关键词:
慢性阻塞性肺疾病;  温肺祛痰散;  缩唇腹式呼吸;  痰浊阻肺型;  稳定期;  外周血T淋巴细胞;  生活质量
Keywords:
Chronic obstructive pulmonary disease;  Wenfei Qutan powder;  Lip-contraction abdominal breathing;  Phlegm-obstructed lung type;  Stable phase;  Peripheral blood T-lymphocytes;  Quality of life
分类号:
R 563.9
DOI:
DOI:10.3969/j.issn.1000-7369.2025.01.012
文献标志码:
A
摘要:
目的:观察温肺祛痰散对稳定期慢性阻塞性肺疾病(COPD)患者外周血T淋巴细胞、血清白细胞介素-2(IL-2)及可溶性白细胞介素-2受体(sIL-2R)的影响,为临床治疗提供参考。方法:选取痰浊阻肺型稳定期COPD患者60例,采用随机数字表法分为两组,每组30例。两组患者均给予缩唇腹式呼吸。对照组给予噻托溴铵治疗,观察组给予噻托溴铵+温肺祛痰散治疗。记录两组治疗前、治疗后中医症候积分、咳嗽评分、生活质量评分及外周血T淋巴细胞、血清IL-2、sIL-2R水平变化,并记录两组疗效和COPD急性发作次数。结果:观察组治疗8周总有效率高于对照组,随访6个月内COPD急性发作次数少于对照组(P<0.05); 治疗后两组生活质量评分、CD3+、CD4+、CD4+/CD8+、IL-2升高(P<0.05),中医症候积分、咳嗽评分、CD8+、sIL-2R降低(P<0.05),观察组生活质量评分、CD3+、CD4+、CD4+/CD8+、IL-2高于对照组(P<0.05),中医症候积分、咳嗽评分、CD8+、IL-2、sIL-2R低于对照组(P<0.05)。结论:温肺祛痰散可提高稳定期COPD患者免疫功能,调节血清IL-2及sIL-2R的表达,改善症状,提高生活质量。
Abstract:
Objective:To observe the effects of Wenfei Qutan powder on peripheral blood T lymphocytes,serum interleukin-2(IL-2)and soluble interleukin-2 receptor(sIL-2R)in patients with stable chronic obstructive pulmonary disease(COPD),and to provide reference for clinical treatment.Methods:Sixty patients with stable COPD of phlegm obstructing lung type were selected and divided into two groups of 30 cases each using the random number table method.Both groups were given lip-contraction abdominal breathing.The control group was given tiotropium bromide treatment,and the observation group was given tiotropium bromide + warm lung expectorant powder treatment.The changes in TCM symptom score,cough score,quality of life score and peripheral blood T lymphocyte,serum IL-2 and sIL-2R levels were recorded before and after the treatment in both groups,and the total effective rate of clinical treatment and the number of COPD acute exacerbations in patients with 6-month follow-up were counted in both groups.Results:The total effective rate of the observation group was higher than that of the control group in 8 weeks of treatment,and the number of COPD acute exacerbations in 6 months of follow-up was less than that of the control group,the difference was statistically significant(P<0.05).After treatment,QOL,CD3+,CD4+,CD4+/CD8+ and IL-2 were increased(P<0.05),while TCM syndrome score,cough score,CD8+ and sIL-2R were decreased(P<0.05).Qol,CD3+,CD4+,CD4+/CD8+ and IL-2 in observation group were higher than those in control group(P<0.05),while TCM syndrome score,cough score,CD8+,IL-2 and sIL-2R in observation group were lower than those in control group(P<0.05).Conclusion:Wenfei Qutan powder can improve the immune function of stable COPD patients,regulate the expression of serum IL-2 and sIL-2R,improve symptoms and improve the quality of life.

参考文献/References:

[1] 林泽辉,许银姬.慢性阻塞性肺疾病急性加重患者住院死亡结局预测模型研究[J].临床肺科杂志,2020,25(8):1175-1179.
[2] HIMANSHU G,ANAS A,NABEELA N,et al.Posterior reversible encephalopathy syndrome due to chronic obstructive pulmonary disease[J].Canadian Journal of Neurological Sciences,2020,47(4):569-571.
[3] 韦晓颖,王彬,高峰.从痰瘀论治慢性阻塞性肺疾病急性加重[J].国际中医中药杂志,2023,45(4):504-507.
[4] 孙红红,武自力,何永杰,等.咳喘敷贴治疗慢性阻塞性肺疾病急性发作期疗效分析[J].中国中西医结合急救杂志,2020,27(3):287-290.
[5] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255-264.
[6] 朱文锋,何清湖.现代中医临床诊断学[M].北京:人民卫生出版社,2003:528-529.
[7] 国家食品药品监督管理局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:65.
[8] 中华医学会呼吸病学分会哮喘学组.咳嗽的诊断与治疗指南(2009版)[J].中华结核和呼吸杂志,2009,19(22):1-7.
[9] 胡思源.儿童咳嗽变异性哮喘中药临床试验设计与评价技术指南[J].药物评价研究,2021,44(8):1621-1627.
[10] 秦晋,韦振平,宋萍.渐进式抗阻训练联合肺康复运动对老年COPD稳定期患者心理状态、肺功能及生活质量的影响[J].保健医学研究与实践,2023,20(10):47-51.
[11] EL-RAHMAN A,RABAB A,EL-WAHSH S.Comorbidities in chronic obstructive pulmonary disease patients[J].The Egyptian Journal of Chest Diseases and Tuberculosis,2020,69(2):310-315.
[12] 杨旖,何萍,李群,等.噻托溴铵粉雾剂联合沙美特罗替卡松治疗老年支气管哮喘-慢阻肺重叠综合征的疗效[J].保健医学研究与实践,2024,21(6):43-48.
[13] 徐梦娇,晏军,张迪,等.中医药多靶点治疗慢性阻塞性肺疾病机制的研究概论[J].世界中医药,2023,18(16):2396-2401.
[14] 章程,胡春媚,李映霞,等.基于中医传承辅助平台的国医大师洪广祥辨治慢阻肺经验研究[J].江西中医药,2022,53(2):29-33.
[15] 梁颜,陈立国,王富春.基于现代穴位敷贴治疗慢性阻塞性肺疾病选穴及用药规律分析[J].吉林中医药,2018,38(4):373-377.
[16] 王伟,足巴措,张旭.补肺汤治疗慢性阻塞性肺疾病急性加重期疗效及对患者Th1/Th2漂移的影响[J].陕西中医,2023,44(8):1078-1081.
[17] 王丹,殷璀颖,蔡莉娟.中药穴位贴敷联合耳穴贴压治疗慢性阻塞性肺疾病急性加重期痰浊阻肺证临床研究[J].新中医,2023,55(8):193-197.
[18] 李燕玲,秦小琪,郭路瑶,等.套细胞淋巴瘤外周血CD4+/CD8+比值与预后的相关性分析[J].中国实验血液学杂志,2024,32(4):1129-1135.
[19] 郑一,刘继伟,于喜红,等.不同表型COPD患者HRCT参数与T淋巴细胞亚群水平、肺功能参数的相关性[J].分子诊断与治疗杂志,2023,15(1):43-47.
[20] 赵萌,赵育周,赵志娟,等.T淋巴细胞亚群在慢性阻塞性肺疾病发生、发展中的作用研究进展[J].检验医学与临床,2023,20(5):705-709.
[21] 黄晓慧,康娟,何昭錡,等.COPD合并肺结核患者TNF-α和IFN-γ与sIL-2R及CRP的表达[J].中华医院感染学杂志,2022,32(6):875-879.
[22] 文小竹,谭光波,朴金安.补肺健脾益肾方对COPD模型大鼠 TLR4/MyD88/NF-κB通路相关因子的影响[J].陕西中医,2021,42(9):1163-1166.
[23] 吴秋静,史可云,胡杰,等.老年COPD患者合并结核分枝杆菌感染的危险因素及IFN-γ、sIL-2R、Ag85B水平变化[J].中华医院感染学杂志,2024,34(9):1336-1339.
[24] 吴婉,姜苗,许婷媛,等.老年稳定期慢性阻塞性肺疾病患者血清C-反应蛋白和白细胞介素-6表达与1年内频繁发作关系研究[J].陕西医学杂志,2024,53(3):352-356.

相似文献/References:

[1]杨栓柱,王 文 △,李 猛,等.千金苇茎汤合瓜蒌薤白杏仁汤治疗 慢性阻塞性肺疾病急性加重期临床研究*[J].陕西中医,2019,(5):600.
[2]王 敏,陈 阁.清热化痰祛瘀方联合西药治疗慢性阻塞性肺疾病急性 加重期患者的临床研究[J].陕西中医,2019,(5):610.
　WANG Min,CHEN Ge..Clinical study of Qingre Huatan Quyu prescription combined with western medicine in the treatment of acute exacerbation of chronic obstructive pulmonary disease[J].,2019,(1):610.
[3]李天浩,韩晨旭,王惠琴,等.基于EGFR-MUC5AC信号通路探讨参鱼化痰口服液干预慢性阻塞性肺疾病大鼠气道黏液高分泌的机制*[J].陕西中医,2019,(8):995.
　LI Tianhao,HAN Chenxu,WANG Huiqin,et al.Based on EGFR-MUC5AC signaling pathway to explore the mechanism of Shenyu Huatan oral liquid in intervention of airway mucus high secretion in COPD rats[J].,2019,(1):995.
[4]王珊珊,谭光波△.补肺汤对慢性阻塞性肺疾病肺气肿大鼠血清IFNγ、IL4表达水平影响研究*[J].陕西中医,2019,(11):1491.
　WANG Shanshan,TAN Guangbo..Effect of Bufei decoction on the expression of IFNγ and IL4 in serum of rats with chronic obstructive pulmonary disease and emphysema[J].,2019,(1):1491.
[5]任英杰,王 起,陈秋生.黄芪汤加减治疗急性加重期慢性阻塞性肺疾病疗效研究[J].陕西中医,2020,(1):57.
　REN Yingjie,WANG Qi,CHEN Qiusheng..Observation on the curative effect of Huangqi decoction in the treatment ofacute exacerbation of chronic obstructive pulmonary disease[J].,2020,(1):57.
[6]聂清华,范伏元△.射干麻黄汤联合沙丁胺醇对慢性阻塞性肺疾病患者肺功能、生活质量的影响[J].陕西中医,2020,(2):180.
　NIE Qinghua,FAN Fuyuan..Effects of Shegan Mahuang decoction and albuterol on pulmonary function and quality of life in patients with COPD[J].,2020,(1):180.
[7]刘新平,王展儒.理肺化痰通脉方治疗慢性阻塞性肺疾病急性加重期临床研究[J].陕西中医,2020,(4):484.
[8]杜沂岚,唐 敏,陈朝晖△,等.经肺腧穴中药离子导入联合振动排痰治疗慢性阻塞性肺疾病急性加重期临床疗效*[J].陕西中医,2020,(4):534.
　DU Yilan,TANG Min,CHEN Zhaohui,et al.Clinical efficacy of Chinese medicine iontophoresis via Feishu point combined with vibration sputum discarding in the treatment of AECOPD[J].,2020,(1):534.
[9]唐颖丽,谢 珊,余清萍,等.子午流注法治疗慢性阻塞性肺疾病加重期痰浊阻肺证疗效研究*[J].陕西中医,2020,(9):1311.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.039]
　TANG Yingli,XIE Shan,YU Qingping,et al.Curative effect of midnight-noon ebb-flow method on chronic obstructive pulmonary disease exacerbation with syndrome of Tanzhuo Zufei[J].,2020,(1):1311.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.039]
[10]蔡东林,孙钟和,赵益庆.慢性阻塞性肺疾病稳定期BODE指数、IL-8、TNF-α水平与肺肾气虚证相关性研究*[J].陕西中医,2020,(11):1573.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.015]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(82305291); 江苏省张家港市科技计划项目(ZKS1915)
更新日期/Last Update: 2025-01-09